Conference Proceedings
004 Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis
Wei Z Yeh, Putu A Widyastuti, Anneke Van der Walt, Jim Stankovich, Eva K Havrdova, Dana Horakova, Karolina Vodehnalova, Serkan Ozakbas, Sara Eichau, Pierre Duquette, Tomas Kalincik, Francesco Patti, Cavit Boz, Murat Terzi, Bassem Yamout, Jeannette Lechner-Scott, Patrizia Sola, Olga Skibina, Michael Barnett, Marco Onofrj Show all
Oral abstracts | BMJ Publishing Group Ltd | Published : 2021
Abstract
To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort. Data were obtained from the MSBase Registry. Term/preterm pregnancies conceived from 2011-2019 were included (modern cohort). Annualised relapse rates (ARR) were calculated before, during and after pregnancy. Predictors of intrapartum and early postpartum (1st3 months) relapse were determined by clustered logistic and Cox regression analyses, respectively. We included 1640 pregnancies from 1452 women. Disease-modifying therapy (DMT) used in the one-year preconception included natalizumab (n=219), fingolimod (n=147), dimethyl fumarate (DMF; n=57) and low-efficacy therapies (n=845). Preconceptio..
View full abstract